New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 26, 2018 - The FDA approved the deletion of two indications and related information from Sandoz’s Erelzi (etanercept-szzs) drug label.
Download PDF
Return to publications
